1. Home
  2. List
Reference Patent

Reference - List

When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 107 Hits
  • Search Condition : Filter (MeSH = Lung Neoplasms / drug therapy*)
Species Resource Title
Human and Animal Cells LLC(RCB0558) Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice.
Human and Animal Cells EBC-1(RCB1965) Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.
Human and Animal Cells II-18(RCB2093) , PC-14(RCB0446) , RERF-LC-KJ(RCB1313) Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Human and Animal Cells A549(RCB0098) Upregulation of Chemoresistance by Mg2+ Deficiency through Elevation of ATP Binding Cassette Subfamily B Member 1 Expression in Human Lung Adenocarcinoma A549 Cells.
Human and Animal Cells LC-2/ad(RCB0440) HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Human and Animal Cells LM8(RCB1450) The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
Human and Animal Cells Ba/F3(RCB0805) Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Human and Animal Cells PC-9(RCB4455) A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
Human and Animal Cells A549(RCB0098) Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.
Human and Animal Cells LU99(RCB1900) , LU65(RCB1967) , IA-LM(RCB0554) The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Human and Animal Cells A549(RCB0098) Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Human and Animal Cells RERF-LC-KJ(RCB1313) , LC-1/sq(RCB0455) , RERF-LC-AI(RCB0444) , MS-1(RCB0725) PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Human and Animal Cells PC-9(RCB4455) Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Human and Animal Cells PC-9(RCB4455) Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Human and Animal Cells PC-9(RCB4455) Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Human and Animal Cells A549(RCB0098) Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
Human and Animal Cells PC-9(RCB4455) Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Human and Animal Cells LC-2/ad(RCB0440) Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma.
Human and Animal Cells LC-2/ad(RCB0440) Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.
Human and Animal Cells MRC-5 Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.